6 independently detected trends connected to this subject, with the latest coverage first.
This hub groups 6 separate news trends connected to Takeda, spanning July 21, 2026 through September 11, 2026. Each event page combines source coverage, attention velocity and a time-stamped explanation instead of treating every headline as a separate story.
The record below represents 48 article observations and 45 source signals, led by Business, Health coverage. Use it to compare how individual events emerged, spread and changed over time.
Takeda announces Andy Plump’s June 2027 retirement after steering back‑to‑back approvals and a major pipeline overhaul.
A first‑in‑class orexin agonist cleared global hurdles, promising a new wake‑up call for narcolepsy sufferers.
A new narcolepsy drug clears Phase 3, earning acclaim and prompting talks of a neuroscience breakthrough.
Silence Therapeutics' new data on a rare blood cancer drug could disrupt Takeda's market position.
Takeda's narcolepsy drug Orzeyful is the first FDA-approved treatment to target the underlying cause of narcolepsy Type 1.
Takeda's Qdenga has become the first dengue vaccine approved for use in India, targeting one of the world's most at-risk populations.